TY  - JOUR
AU  - Dietlein, Felix
AU  - Mueller, Peter
AU  - Kobe, Carsten
AU  - Endepols, Heike
AU  - Hohberg, Melanie
AU  - Zlatopolskiy, Boris
AU  - Krapf, Philipp
AU  - Heidenreich, Axel
AU  - Neumaier, Bernd
AU  - Drzezga, Alexander
AU  - Dietlein, Markus
TI  - [18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer
JO  - Molecular imaging and biology
VL  - 23
IS  - 2
SN  - 1536-1632
CY  - Cham
PB  - Springer Nature Switzerland
M1  - FZJ-2021-02680
SP  - 277-286
PY  - 2021
AB  - Purpose: PSMA imaging is frequently used for monitoring of androgen deprivation therapy(ADT) in prostate cancer. In a previous study, [18F]-JK-PSMA-7 exhibited favorable propertiesfor tumor localization after biochemical recurrence. In this retrospective study, we evaluated theperformance of [18F]-JK-PSMA-7 under ADT.Procedures: We examined the performance of [18F]-JK-PSMA-7 in 70 patients (first cohort) withincreasing or detectable PSA values under ADT (PSA G 2 ng/ml for 21/70 patients). We furtheranalyzed 58 independent patients with PSA levels G 2 ng/ml under ADT, who were imaged with[68Ga]PSMA-11 or [18F]DCFPyL (second cohort). Finally, we compared detection rates between[18F]-JK-PSMA-7, [68Ga]PSMA-11, and [18F]DCFPyL.Results: In the first cohort, we detected [18F]-JK-PSMA-7-positive lesions in 63/70 patients. Inpatients with PSA levels ≥ 2 ng/ml, the detection rate was 100 % (49/49). In patients with PSA G 2ng/ml, the detection rate was significantly lower (66.7 %, 14/21, p = 9.7 × 10−5) and dropped from85.7%(12/14, PSA levels between 0.3 and 2.0 ng/ml) to 28.6%(2/7) for PSA levels G 0.3 ng/ml (p =1.73 × 10−2). In the second cohort (PSA G 2 ng/ml), the detection rate was 79.3 % (46/58) for[68Ga]PSMA-11 or [18F]DCFPyL. Again, the detection rate was significantly higher (p = 1.1 × 10−2)for patients with PSA levels between 0.3 and 2.0 ng/ml (87.0 %, 40/46) relative to those with PSAlevels G 0.3 ng/ml (50 %, 6/12). No significant difference was found between [18F]-JK-PSMA-7 and[68Ga]PSMA-11 or [18F]DCFPyL in patients with PSA levels G 2 ng/ml (p = 0.4295).Conclusion: [18F]-JK-PSMA-7 PET showed a high detection rate in patients with PSA levels ≥0.3 ng/ml under ADT. The lower PSA threshold of 0.3 ng/ml for high detection rates wasconsistent across the three PSMA ligands. Thus, PSMA imaging is suitable for clinical follow-upof patients with increasing PSA levels under ADT.
LB  - PUB:(DE-HGF)16
C6  - 33006028
UR  - <Go to ISI:>//WOS:000574311700001
DO  - DOI:10.1007/s11307-020-01546-0
UR  - https://juser.fz-juelich.de/record/893306
ER  -